Methylprednisolone N Acetylcysteine in Hepatic Resections (MENHIR)
Ischemic Reperfusion Injury, Insufficiency; Hepatic, Postoperative, Liver Tumour
About this trial
This is an interventional treatment trial for Ischemic Reperfusion Injury focused on measuring N-Acetylcysteine, Methylprednisolone, Liver ischemia reperfusion injury, Pringle manoeuvre, Hepatic resection
Eligibility Criteria
Inclusion Criteria:
- Any sex, any race, any ethnicity
- Age > 18
- Primary and secondary liver tumors
- Normal renal function
- Anticipated Pringle's length > 30 minutes
Exclusion Criteria:
- Renal failure of any grade
- ASA 4
- Associate major surgery
- Intraoperative bleeding > 1500 ml
- Allergy to N-acetylcysteine or Methylprednisolone
Sites / Locations
- Istituto Clinico Humanitas IRCCS
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
N-acetylcysteine
Methylprednisolone
Placebo
Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).